Invention Application
- Patent Title: TREATMENT WITH ANTI-EFNA4 ANTIBODY-DRUG CONJUGATES
-
Application No.: US15573303Application Date: 2016-05-12
-
Publication No.: US20180099054A1Publication Date: 2018-04-12
- Inventor: ASHWIN GOLLERKERI , KAREN VELASTEGUI , RAFFAELE BAFFA , JAYMES SCOT HOLLAND
- Applicant: PFIZER INC. , RINAT NEUROSCIENCE CORP.
- Applicant Address: US NY NEW YORK US CA SOUTH SAN FRANCISCO
- Assignee: PFIZER INC.,RINAT NEUROSCIENCE CORP.
- Current Assignee: PFIZER INC.,RINAT NEUROSCIENCE CORP.
- Current Assignee Address: US NY NEW YORK US CA SOUTH SAN FRANCISCO
- International Application: PCT/US2016/032164 WO 20160512
- Main IPC: A61K47/50
- IPC: A61K47/50 ; C07K16/28 ; A61P35/00 ; A61K48/00
Abstract:
The present invention provides for dosing regimens for the treatment of patients with cancer and/or an EFNA4-associated disorder with an anti-EFNA4 antibody-drug conjugate (ADC). The present invention further provides for methods for the treatment of patients with cancer and/or an EFNA4-associated disorder in which an anti-EFNA4 ADC is administered intravenously weekly (QW) or every 3 weeks (Q3W).
Information query
